Affymetrix's second quarter revenues grew 10.3% to $88.3 million.Affymetrix's second quarter revenues grew 10.3% to $88.3 million. Product revenue improved 4.8% to $64.0 million. DNA chip DNA chip See DNA microarray. Noun 1. DNA chip - a microchip that holds DNA probes that form half of the DNA double helix and can recognize DNA from samples being tested gene chip sales increased 65%, but were partially offset by a 3% decline in RNA RNA: see nucleic acid. RNA in full ribonucleic acid One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic chip sales. Reagents sales climbed 47.0% to $14.2 million due to increased volume and higher average pricing. Probe arrays sales rose 2.1% to $41.0 million, due to strong growth for genotyping Genotyping refers to the process of determining the genotype of an individual with a biological assay. Current methods of doing this include PCR, DNA sequencing, and hybridization to DNA microarrays or beads. . Over 30% of genotyping sales were driven by the new SNP SNP Scottish National Party Noun 1. SNP - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily 6.0 genotyping chip. However, this growth was partially offset by lower average selling prices The average sales price of goods or commodities. Especially used in the retail sector and technology distribution. of probe arrays. Instrument revenues declined 21.6% to $8.8 million, of which $1.6 million was a result of lower selling prices of the GeneChip Scanner 3000. Product-related revenue jumped 19.2% to $17.2 million benefiting from the genotyping services business. Consequently, service and other revenue jumped 37% to $12.5 million. License fees and milestone revenue improved 3.3% to $3.7 million, while subscription fees declined 42.3% to $1.0 million. Royalties and other revenue increased 12.9% to $2.7 million primarily due to additional license and grant revenue, while revenue from Perlegen Sciences soared 101.3% to $4.4 million. Pricing pressure for probe arrays, instruments and reagents led gross margins to fall 620 basis points to 58.6% of revenues. The company's adjusted operating loss operating loss The excess of operating expenses over revenue. As with operating income, operating losses exclude revenues and expenses from operations that are not considered a regular part of the business. Also called deficit. Compare operating income. benefited from lower R&D and SG&A costs and narrowed to $1.3 million from a loss of $9.1 million. For fiscal 2007, revenues are estimated to be $365-$385 million with gross margins of around 60%. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion